FISF Cryptococcal study in other than HIV patients
Not Applicable
- Conditions
- Health Condition 1: B459- Cryptococcosis, unspecified
- Registration Number
- CTRI/2024/05/066953
- Lead Sponsor
- Fungal Infection Study Forum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Adult patient with age more than 18 years with first episode of CM and or CC
2. Diagnosis of CM arrived by CSF Cryptococcal Antigen (CrAg) Positive or Positive Cryptococcal culture, India Ink, Cryptococcal PCR
3. Blood culture positive for cryptococcus
4. BAL culture positive for cryptococcus, or BAL CrAg titer more than 1: 8,
5. Serous cavity (ascites, pleural or pericardial) fluids CrAg, culture, PCR positive
6. Tissue biopsy showing characteristics yeast cells and/or serum or BAL CrAg positive.
Exclusion Criteria
1. Not willing to participate or refuse consent.
2. HIV infected patients
3. Pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical characteristics, risk factors and outcome of non HIV CM and CC <br/ ><br>Duration of anti fungal treatment and outcomeTimepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method To study cryptococcal species & its drug susceptibility in non-HIV associated CM <br/ ><br>Difference in clinical presentation & outcome of C. gatii versus C. Neoformans <br/ ><br>Treatment & outcome of patients with CC Species distributions & Drug susceptibility pattern & outcome at 8 & 12 weeks <br/ ><br>Incidence of PR following antifungal treatment for CM <br/ ><br>Reduction in the immunosuppression (overall, specific agent) & PR <br/ ><br>Timepoint: 12 weeks